Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00339703 · ClinicalTrials.gov registry record

Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.

A clinical trial, sponsored by 59th Medical Wing.

Completed
Registry status
44
Enrollment target

NCT00339703 is a clinical trial that has completed, run by 59th Medical Wing. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00339703 has completed, sponsored by 59th Medical Wing.

COMPLETED
Registry status
44 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether serum resistin levels in asthmatics are elevated. We will recruit subjects from the allergy/immunology clinic with a prior diagnosis of moderate to severe persistent asthma in addition to subjects being seen for evaluation of drug allergies. Based on the inclusion and exclusion criteria below, subjects will be placed into a control and asthma group. Each subject will undergo one blood draw in the main lab at WHMC, and return a lavender top tube to the allergy/immunology clinic for the EIA resistin assay. The patient will then have a brief encounter with a physician to determine an up to date history of asthma symptoms prior to participating in the exhaled NO test. The entire subject encounter will take place with one clinic visit, and requires no follow up visits as part of the study. The greatest risk to each subject will be the blood draw, as the exhaled NO is a completely non-invasive test. Plasma from each subject will be stored in a -70° freezer for no more than one month. Samples will be analyzed for resistin levels using an EIA assay run monthly. Mean values from serum CRP, serum glucose, serum resistin, and exhaled NO will be compared using a students T-test.

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2004-11
Est. Completion 2006-05

Sponsor

59th Medical Wing

20 total trials

What the Registry Record Tells You About NCT00339703

The ClinicalTrials.gov registry entry for NCT00339703 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 59th Medical Wing, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00339703 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00339703 about?

NCT00339703 is a clinical study titled "Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.". The purpose of this study is to determine whether serum resistin levels in asthmatics are elevated. We will recruit subjects from the allergy/immunology clinic with a prior diagnosis of moderate to severe persistent asthma in addition to subjects being seen for evaluation of drug allergies. Based on...

What is the current status of trial NCT00339703?

This trial is currently completed. The enrollment target is 44 participants. The study started on 2004-11. Estimated completion is 2006-05.

Who is sponsoring clinical trial NCT00339703?

This trial is sponsored by 59th Medical Wing, which has 20 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.